How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Vitamin D3 (Cholecalciferol) Market
- By Form: Softgel Capsules, Tablets, Powder, Liquid Drops, Chewable Tablets
- By Source: Lanolin-derived, Fish Oil-derived, Lichen-derived (Vegan)
- By Application: Dietary Supplements, Pharmaceuticals, Functional Foods & Beverages, Animal Feed
- By End User: Adults, Infants & Children, Elderly, Pregnant Women
- By Distribution Channel: Pharmacies, Online Retail, Health Food Stores, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Softgel Capsules leads By Form at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Vitamin D3 (Cholecalciferol) Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →DSM Nutritional Products
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Fermenta Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Hubei Guangji Pharmaceutical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Jiangsu Yabang Pharmaceutical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Zhejiang NHU Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Luye Pharma Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Gnosis by Lesaffre
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Jiangsu Kanion Pharmaceutical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jiangxi Tianxin Pharmaceutical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Shandong Dong-E E-Jiao Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mingtai Chemical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Wuhan Yuancheng Gongchuang Technology
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Jiangsu Yuyuan Pharmaceutical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Jiangsu Yabang Pharmaceutical Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Alfa Aesar (Thermo Fisher Scientific)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Softgel Capsules50.2
- Tablets14.7
- Powder13.8
- Liquid Drops13.9
- Chewable Tablets7.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- DSM Nutritional Products21.8
- Fermenta Biotech23.8
- Hubei Guangji Pharmaceutical4.5
- Jiangsu Yabang Pharmaceutical9.8
- Zhejiang NHU Co. Ltd.5.5
- Luye Pharma Group6.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe21.6
- Asia Pacific21.0
- Latin America12.0
- Middle East and Africa10.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| DSM Nutritional Products | 96 | 76 | 86 | 75 | 86 | 90 | 85 |
| Fermenta Biotech | 71 | 78 | 90 | 80 | 75 | 74 | 78 |
| Hubei Guangji Pharmaceutical | 85 | 86 | 67 | 79 | 70 | 80 | 78 |
| Jiangsu Yabang Pharmaceutical | 57 | 57 | 67 | 75 | 63 | 81 | 67 |
| Zhejiang NHU Co. Ltd. | 69 | 54 | 60 | 60 | 62 | 59 | 61 |
| Luye Pharma Group | 48 | 61 | 53 | 46 | 67 | 49 | 54 |
| Gnosis by Lesaffre | 53 | 59 | 46 | 42 | 46 | 56 | 50 |
| Jiangsu Kanion Pharmaceutical | 41 | 40 | 52 | 44 | 60 | 54 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- DSM Nutritional Products
- Fermenta Biotech
- Hubei Guangji Pharmaceutical
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| DSM Nutritional Products | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Fermenta Biotech | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Hubei Guangji Pharmaceutical | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Jiangsu Yabang Pharmaceutical | − | − | ◐ | ◐ | − | ◐ |
| Zhejiang NHU Co. Ltd. | ◐ | − | ◐ | − | ✓ | ◐ |
| Luye Pharma Group | − | ◐ | ◐ | − | ◐ | − |
| Gnosis by Lesaffre | ◐ | − | − | − | − | ◐ |
| Jiangsu Kanion Pharmaceutical | − | − | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Form in North America, then scale across Vitamin D3 (Cholecalciferol) Market — a $259M beachhead inside a $4.02B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Softgel Capsules
Best fit — highest urgency & budget in Form.
Tablets
Strong fit — clear ROI and a fast path to value.
Powder
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Form in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Form leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Vitamin D3 (Cholecalciferol) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Vitamin D3 (Cholecalciferol) Market is a high-growth opportunity — $3.10B by 2033, compounding at 10.5%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.5% CAGR
Demand compounds through 2033, outpacing GDP across Form.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Form moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Vitamin D3 (Cholecalciferol) Market — a $7.02B market by 2033. Plan: grow share from 10.3% to 17.0%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.3% | 17.0% | Ahead |
| Revenue | $661M | $1.19B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.7% | 44.3% | Ahead |
| Customer retention | 85.7% | 92.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Form
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Source capability
A defensible second engine — invest in Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Form share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $155M capacity & capability investment
- Greenlight bolt-on M&A in Source
- Authorise North America expansion plan
- Fund R&D program for Form leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentOn track
Sales deck · value proposition
Win the Vitamin D3 (Cholecalciferol) Market conversation — a $8.25B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Form
Goal Grow share in Form
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Vitamin D3 (Cholecalciferol) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Vitamin D3 (Cholecalciferol) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Milk Thistle Extracts Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportIon Selective Permeable Membrane Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportGlutamine (Gln) Market
Glutamine (Gln) Market is valued at USD 520 Million in 2025 and is expected to reach USD 735 Mi…
$520M market · 2025 base year
View reportDienogest Tablets Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportDienogest API Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportWater-based Pharmaceutical Ink Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportUnnatural Amino Acids Market
Market size, share, segmentation and regional forecast.
$343M market · 2025 base year
View reportTemperature Controlled Pharmaceutical Packaging Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportSynbiotics Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportSucrose Acetate Isobutyrate (SAIB) Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportRotundine Market
Market size, share, segmentation and regional forecast.
$631M market · 2025 base year
View reportRadiation Shielding Curtains Market
Market size, share, segmentation and regional forecast.
$576M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy